Anlotinib
- Generic Name
- Anlotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22FN3O3
- CAS Number
- 1058156-90-3
- Unique Ingredient Identifier
- GKF8S4C432
- Background
Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.
- Indication
用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。
用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT04236362
- Locations
- 🇨🇳
The General Hospital of the People's Liberation Army, Beijing, Beijing, China
🇨🇳The First Hospital of Lanzhou University, Lanzhou, Gansu, China
🇨🇳Cancer Hospital of Chongqing University, Chongqing, Chongqing, China
A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 738
- Registration Number
- NCT04234607
- Locations
- 🇨🇳
Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
Anlotinib Treatment in Steroid Depenent/Refractory cGVHD
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2021-03-24
- Target Recruit Count
- 5
- Registration Number
- NCT04232397
- Locations
- 🇨🇳
Hematology Department, Shanghai, Shanghai, China
A Study of Anlotinib in Subjects With Advanced Malignancy
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 93
- Registration Number
- NCT04216082
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2019-12-26
- Target Recruit Count
- 70
- Registration Number
- NCT04211896
A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT04207463
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Jilin, China
A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT04203719
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT04197492
- Locations
- 🇨🇳
CyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai, Shanghai, China
Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Jinglong Chen
- Target Recruit Count
- 48
- Registration Number
- NCT04157140
- Locations
- 🇨🇳
Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Dalian Medical University, Dalian, China
🇨🇳Shengjing Hospital Of China Medical University, Shenyang, China
Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04147728
- Locations
- 🇨🇳
Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North Garden Rd.,Haidian Dist., Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.